Research
Cellular
GLP‐1RAs triggered more gastrointestinal adverse events than placebo, with no in‐between difference.
Clinicians should be aware of the gastrointestinal side effects associated with GLP-1RAs when prescribing these medications.
StrongSupportsmedium confidence
GLP‐1RAs triggered more gastrointestinal adverse events than placebo, with no in‐between difference.
Why this rating
Based on a network meta-analysis of seven RCTs with over 12,300 patients.
Source
Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials
Omar S. Alkhezi et al. · Obesity Reviews · 2022
DOI 10.1111/obr.13543
Meta-analysisCited 132×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weekly tirzepatide 10 and 15 mg resulted in more weight loss than weekly semaglutide 2.4 mg, daily semaglutide 0.4 mg, or liraglutide 3 mg.Strong
- Tirzepatide and weekly semaglutide demonstrated comparable results but with significantly higher odds of achieving ≥5%–20% weight loss compared with liraglutide.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →